Antithrombotic agents. Fondaparinux in acute coronary syndromes: improved efficacy and safety

Affiliations

Comment

David P Faxon. Rev Cardiovasc Med. 2006 Summer.

. 2006 Summer;7(3):166-7.

¹ Harvard Medical School, Brigham and Women's Hospital, Boston, Massachusetts, USA.

No abstract available

Comment on

Comparison of fondaparinux and enoxaparin in acute coronary syndromes.
Fifth Organization to Assess Strategies in Acute Ischemic Syndromes Investigators; Yusuf S, Mehta SR, Chrolavicius S, Afzal R, Pogue J, Granger CB, Budaj A, Peters RJ, Bassand JP, Wallentin L, Joyner C, Fox KA. Fifth Organization to Assess Strategies in Acute Ischemic Syndromes Investigators, et al. N Engl J Med. 2006 Apr 6;354(14):1464-76. doi: 10.1056/NEJMoa055443. Epub 2006 Mar 14. N Engl J Med. 2006. PMID: 16537663 Clinical Trial.
Effects of fondaparinux on mortality and reinfarction in patients with acute ST-segment elevation myocardial infarction: the OASIS-6 randomized trial.
Yusuf S, Mehta SR, Chrolavicius S, Afzal R, Pogue J, Granger CB, Budaj A, Peters RJ, Bassand JP, Wallentin L, Joyner C, Fox KA; OASIS-6 Trial Group. Yusuf S, et al. JAMA. 2006 Apr 5;295(13):1519-30. doi: 10.1001/jama.295.13.joc60038. Epub 2006 Mar 14. JAMA. 2006. PMID: 16537725 Clinical Trial.